Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated with Tucatinib

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated with Tucatinib

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to test a program that is being developed by nurses to help patients with HER2+ metastatic breast cancer manage their treatment with three drugs typically used for this diagnosis: tucatinib, trastuzumab, and capecitabine. The program's goal is to help patients manage symptoms and provide resources to improve their quality of life.

Who Can Participate?

Eligibility

Women ages 18+ who:
  • Are diagnosed with HER2+ metastatic breast cancer
  • Are being treated with tucatinib, trastuzumab, and capecitabine
For more information, contact the study team at michael.w.willis@duke.edu.

Age Range

18-110

Sex/Genders

Female (cisgender)
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to participate, you will be asked to:
  • Meet with a nurse navigator via Zoom for three sessions, about 40 minutes each, over a period of six weeks
  • Complete three surveys, which take about 30 minutes each to complete, over the 6-week study period
  • Be asked to share your feedback about the program during an interview over Zoom

    • Locations

    Remote/online

    Compensation

    Yes

    Spanish Materials Available

    No

    Study Details

    Full Title

    Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated with Tucatinib

    Principal Investigator

    Rebecca
    Shelby

    Protocol Number

    PRO00117920

    NCT ID

    NCT06983691

    Phase

    Pilot

    Enrollment Status

    Open to Enrollment
    ClinicalTrials.gov